Chandan Healthcare Limited — PPTs, 17-08-2026: Investor Presentation

The company delivered strong Q2 FY24 results with revenue up 10.1% YoY to ₹1,007 Cr and H1 revenue reaching ₹1,960 Cr. Profit after tax (PAT) saw a significant jump of 48.6% YoY to ₹60 Cr for Q2 and 39.5% to ₹110 Cr for H1. This robust performance was largely driven by the Pipes & Fittings segment, which grew 13% to ₹870 Cr in Q2, alongside improved profitability from a better product mix and stable raw material prices.

Strategic focus areas include expanding the product portfolio, increasing market share, strengthening the brand, and enhancing operational efficiencies across its vast distribution network.

Key metrics show Q2 EPS stood at ₹2.63, up from ₹1.77 a year ago, with EBITDA margin improving to 12.9%.

Management foresees sustained healthy demand in domestic and international markets, supported by government infrastructure initiatives, housing, and agriculture sectors. The company plans to invest ₹100 Cr in FY24 for capacity expansion and modernization, signaling future growth.